Pharming PHAR Estimates

NASDAQ PHAR
$11.34 -0.12 (-1.05%)
As of: Sep 4, 2026 · 11:24 AM EDT
Analyst Estimates

Pharming Group N.V. Revenue Estimates

Periods 26
Next Period Q3 26
Consensus 101.37 M

Analysts expect Pharming Group N.V. to report revenue of 101.37 M for Q3 26, against a range of 96.05 M to 106.69 M. The most recent reported quarter, Q2 26, came in at 90.20 M, a 12.4% miss against the 102.91 M consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) 74.85 M92.70 M79.09 M93.20 M97.30 M106.50 M72.45 M90.20 M--------
High Estimate 75.39 M86.69 M76.60 M85.88 M112.74 M120.80 M100.48 M109.75 M106.69 M125.32 M79.12 M98.04 M116.72 M132.22 M82.14 M100.51 M
Low Estimate 69.14 M71.40 M65.13 M72.03 M92.68 M110.90 M88.86 M96.07 M96.05 M103.89 M67.76 M80.44 M101.55 M112.42 M73.94 M88.80 M
Consensus Estimate 72.26 M79.04 M70.87 M78.96 M102.71 M115.85 M94.67 M102.91 M101.37 M114.61 M73.44 M89.24 M109.13 M122.32 M78.04 M94.66 M
Analyst Estimates

Pharming Group N.V. Earnings Per Share (EPS) Estimates

Periods 26
Next Period Q3 26
Consensus 0.11

Analysts expect Pharming Group N.V. to report earnings per share of 0.11 for Q3 26, against a range of 0.10 to 0.12. The most recent reported quarter, Q2 26, came in at 0.02, a 66.7% miss against the 0.06 consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) -0.020.05-0.220.060.100.07-0.070.02--------
High Estimate 0.000.02-0.03-0.090.000.010.000.060.120.15-0.010.000.120.170.010.05
Low Estimate 0.000.02-0.03-0.090.000.010.000.060.100.13-0.010.000.100.150.010.05
Consensus Estimate 0.000.02-0.03-0.090.000.010.000.060.110.14-0.010.000.110.160.010.05